XML 28 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating expenses:        
Research and development $ 314,819 $ 79,490 $ 470,791 $ 142,951
General and administrative 18,953 14,521 46,221 28,842
Total operating expenses 333,772 94,011 517,012 171,793
Loss from operations (333,772) (94,011) (517,012) (171,793)
Other income, net 14,178 5,842 18,483 14,071
Loss before provision for income taxes (319,594) (88,169) (498,529) (157,722)
Provision for income taxes 177 2,177 746 3,116
Net loss $ (319,771) $ (90,346) $ (499,275) $ (160,838)
Net loss per share attributable to common shareholders of Biohaven Ltd. — basic (in dollars per share) $ (3.64) $ (1.32) $ (5.93) $ (2.36)
Net loss per share attributable to common shareholders of Biohaven Ltd. — diluted (in dollars per share) $ (3.64) $ (1.32) $ (5.93) $ (2.36)
Weighted average common shares outstanding—basic (in shares) 87,766,069 68,248,023 84,174,099 68,227,564
Weighted average common shares outstanding—diluted (in shares) 87,766,069 68,248,023 84,174,099 68,227,564
Net loss $ (319,771) $ (90,346) $ (499,275) $ (160,838)
Other comprehensive income (loss), net of tax 28 (146) (13) (264)
Comprehensive loss $ (319,743) $ (90,492) $ (499,288) $ (161,102)